APA (7th ed.) Citation

Xie, Y., Chen, Y., Liu, C., Zhao, Y., Gong, C., Lin, S., . . . Yang, Z. (2025). 18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: Impact on progression free survival. European Journal of Nuclear Medicine & Molecular Imaging, 53(1), 374. https://doi.org/10.1007/s00259-025-07459-w

Chicago Style (17th ed.) Citation

Xie, Yizhao, Yifan Chen, Cheng Liu, Yannan Zhao, Chengcheng Gong, Shuyi Lin, Shaoli Song, Biyun Wang, and Zhongyi Yang. "18F-fluoroestradiol (18F-FES) PET/CT for Guiding First-line Treatment in Patients with HR + /HER2- Metastatic Breast Cancer: Impact on Progression Free Survival." European Journal of Nuclear Medicine & Molecular Imaging 53, no. 1 (2025): 374. https://doi.org/10.1007/s00259-025-07459-w.

MLA (9th ed.) Citation

Xie, Yizhao, et al. "18F-fluoroestradiol (18F-FES) PET/CT for Guiding First-line Treatment in Patients with HR + /HER2- Metastatic Breast Cancer: Impact on Progression Free Survival." European Journal of Nuclear Medicine & Molecular Imaging, vol. 53, no. 1, 2025, p. 374, https://doi.org/10.1007/s00259-025-07459-w.